Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2)
Clinical trial NCT07584031 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07584031
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-01
- Primary completion
- 2027-12-31
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.